immune-mediated inflammatory diseases (paediatric)
Immunology · 2024–2024
1decision
1medicine
1carried consumer input
6individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Immune-mediated inflammatory diseases (IMID) in paediatric patients under 18 years of age, to allow children with the greatest risk of permanent disability… | Dec 2024 | Recommended with restriction | 6 individuals Australian Paediatric Rheumatology Group · Juvenile Arthritis Foundation · National Institute · Arthritis Foundation · Rheumatology Research Alliance |
Who spoke
Australian Paediatric Rheumatology Group · Juvenile Arthritis Foundation · National Institute · Arthritis Foundation · Rheumatology Research Alliance
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.